The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysiologic stability in the pig

Cardiovasc Drugs Ther. 1990 Jun;4(3):695-703. doi: 10.1007/BF01856557.

Abstract

The effects of oral zofenopril pretreatment were investigated in a chronic closed-chest pig model of ischemia and reperfusion. Pigs (25-35 kg) were pretreated orally with zofenopril (15 mg/day) on the 2 days prior to ischemia, which was evoked by the inflation of a catheter balloon in the left anterior descending coronary artery over 45 minutes. The catheter was then removed and the myocardium was reperfused. After 2 weeks, infarct properties were assessed by signal averaging of the body surface electrocardiogram and the inducibility of malignant ventricular tachyarrhythmias was tested with a programmed electrical stimulation protocol. A significant increase in the pressure-rate product (43 +/- 11%, mean +/- SEM), indicating the oxygen demand of the heart, was prevented by zofenopril (19 +/- 8%, p less than 0.05). Zofenopril reduced the peak efflux of adrenaline (1302 +/- 213 vs. 3201 +/- 760 pg/ml; p less than 0.05), noradrenaline (402 +/- 54 vs. 902 +/- 282 pg/ml; p less than 0.05), and of the adenosine catabolites inosine and hypoxanthine (56 +/- 4 vs. 78 +/- 9, pg/ml; p less than 0.05) in the coronary venous effluent. The efflux of the cytoplasmatic enzyme creatine phosphokinase was not significantly reduced after zofenopril (p = 0.08). No difference in plasma renin levels between the groups were found. After 2 weeks, late potentials were found only in the surviving animals from the untreated group, i.e., the voltage vector magnitude was more reduced, and a prolongation of the QRS duration and of the terminal low-amplitude part of the high-frequency QRS were found.(ABSTRACT TRUNCATED AT 250 WORDS)

MeSH terms

  • Administration, Oral
  • Angiotensin-Converting Enzyme Inhibitors / administration & dosage
  • Angiotensin-Converting Enzyme Inhibitors / pharmacology*
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Animals
  • Captopril / administration & dosage
  • Captopril / analogs & derivatives*
  • Captopril / pharmacology
  • Captopril / therapeutic use
  • Coronary Disease / enzymology
  • Coronary Disease / prevention & control
  • Creatine Kinase / blood
  • Electric Stimulation
  • Heart / drug effects
  • Heart / physiology
  • Heart Rate / drug effects
  • Hemodynamics / drug effects
  • Male
  • Myocardial Infarction / drug therapy
  • Myocardial Infarction / prevention & control
  • Myocardial Reperfusion Injury / enzymology
  • Myocardial Reperfusion Injury / prevention & control*
  • Myocardium / enzymology
  • Myocardium / metabolism
  • Purines / metabolism
  • Renin / blood
  • Swine
  • Tachycardia / drug therapy
  • Tachycardia / prevention & control
  • Time Factors
  • Ventricular Function / drug effects
  • Ventricular Function / physiology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Purines
  • zofenopril
  • Captopril
  • Creatine Kinase
  • Renin